Pharmacogenomics of Antithrombotic Drugs -a Register Linkage Study With National Registries and Biobanks in Finland

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

7005 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-15

Study Completion Date

2020-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective cohort study linking data from Finnish Biobanks (Helsinki Biobank, Auria Biobank and THL Biobank), laboratory databases, and national registries of Social Insurance Institution of Finland (Kela) and the National Institute of Health and Welfare (THL) to investigate pharmacogenomics of antithrombotic drugs in the Finnish population. The purpose of the study is to assess clinical and economic aspects of using genomic data in the context of antithrombotic drug therapy.

Based on earlier research, data regarding variant alleles in CYP2C9 and VKORC1 will be used in the primary analyses. Individuals with and without specific variant alleles are compared in respect to their clinical response to warfarin therapy. Warfarin-treated individuals are also analysed in relation to other clinical outcomes and a wide range of healthcare encounters.

The explorative part of the study will employ data-driven classification methods to explore genotype-phenotype associations for a larger group of antithrombotic drugs including direct oral anticoagulants, clopidogrel and heparins and possible interactions with other drugs. In this part, 26 gene variants identified in literature will be used.

The retrospective follow-up time for the study participants is from January 2007 to December 2018, or 2 years prior the first anticoagulant drug is purchased until 6 months after the last purchase.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients

NCT07098676

Healthy Individuals (Controls) Vascular Surgery Patients With Acute Thrombosis Dialysis Patients

ENROLLING_BY_INVITATION

Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones

NCT05884060

PNH Thrombosis

COMPLETED

A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"

NCT00334464

Atrial Fibrillation Deep Vein Thrombosis Pulmonary Embolism

COMPLETED NA

Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants

NCT02720328

Embolism and Thrombosis Hemorrhage

COMPLETED PHASE4

Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects

NCT04580602

Stent Thrombosis Ischemic Stroke Myocardial Infarction +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Individuals With a Disease of Cardiovascular System

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-interventional study

This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Genotyped for CYP2C9/rs1799853, CYP2C9/rs1057910 and VKORC1/rs9923231
* Diagnosed with at least one of the following:

* Atrial Fibrillation and Flutter (I48)
* Ischemic Heart Disease (I20-I25)
* Cerebrovascular disease (I63,I65,I66, 167.2, I69.3-I69.8)
* Atherosclerosis (I70)
* Pulmonary embolism (I26)
* Phlebitis and thrombophlebitis (I80)
* Portal vein thrombosis (I81)
* Other venous embolism and thrombosis (I82)
* Purchased at least one of the following drugs between January 1st 2007 - December 31st 2018:

* Anticoagulants: Warfarin, Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Heparin, Enoxaparin, Dalteparin
* Antiplatelets: Clopidogrel, Ticagrelor, Acetylsalicylic acid

Exclusion Criteria

* Permanent residence in Finland less than 12 months during the follow-up period
* Purchase of any of the antithrombotic drugs listed above between January 1st 2005 - December 31st 2006

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes